CN115105482A - 一种降低尿微量白蛋白的泡腾片及其制备方法和应用 - Google Patents
一种降低尿微量白蛋白的泡腾片及其制备方法和应用 Download PDFInfo
- Publication number
- CN115105482A CN115105482A CN202210821693.5A CN202210821693A CN115105482A CN 115105482 A CN115105482 A CN 115105482A CN 202210821693 A CN202210821693 A CN 202210821693A CN 115105482 A CN115105482 A CN 115105482A
- Authority
- CN
- China
- Prior art keywords
- parts
- effervescent tablet
- reducing
- microalbumin
- cherry fruit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007938 effervescent tablet Substances 0.000 title claims abstract description 45
- 230000001603 reducing effect Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 206010027525 Microalbuminuria Diseases 0.000 title abstract description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 45
- 235000005805 Prunus cerasus Nutrition 0.000 claims abstract description 30
- 239000000843 powder Substances 0.000 claims abstract description 26
- 235000009226 Prunus puddum Nutrition 0.000 claims abstract description 25
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 22
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 20
- 210000002700 urine Anatomy 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 239000001508 potassium citrate Substances 0.000 claims abstract description 16
- 229960002635 potassium citrate Drugs 0.000 claims abstract description 16
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims abstract description 16
- 235000011082 potassium citrates Nutrition 0.000 claims abstract description 16
- 239000001509 sodium citrate Substances 0.000 claims abstract description 16
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 16
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 claims abstract description 13
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 13
- 229940013618 stevioside Drugs 0.000 claims abstract description 13
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000019202 steviosides Nutrition 0.000 claims abstract description 13
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 claims abstract description 10
- 239000000600 sorbitol Substances 0.000 claims abstract description 10
- 210000003734 kidney Anatomy 0.000 claims abstract description 8
- 229940109239 creatinine Drugs 0.000 claims abstract description 7
- 230000003907 kidney function Effects 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 5
- 230000036541 health Effects 0.000 claims abstract description 4
- 240000002878 Prunus cerasus Species 0.000 claims description 29
- 230000002485 urinary effect Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 235000015203 fruit juice Nutrition 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 11
- 206010018634 Gouty Arthritis Diseases 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 244000207449 Prunus puddum Species 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 16
- 229940116269 uric acid Drugs 0.000 description 16
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 230000008859 change Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 230000001953 sensory effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 241000167854 Bourreria succulenta Species 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 235000019693 cherries Nutrition 0.000 description 3
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 3
- 229960005101 febuxostat Drugs 0.000 description 3
- 229940063483 febuxostat 40 mg Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000387 litholytic effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/40—Effervescence-generating compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本申请公开了一种降低尿微量白蛋白的泡腾片及其制备方法和应用，属于药品、食品和保健品技术领域。一种降低尿微量白蛋白的泡腾片，包括如下重量配比的原料制备而成：酸樱桃果粉12‑20份、异麦芽酮糖4.0‑5.0份、甜菊糖苷0.4‑0.8份、柠檬酸40‑47份、碳酸钠18‑24份、柠檬酸钠4.5‑5.5份、柠檬酸钾4.5‑5.5份、山梨糖醇4.8‑5.5份。该降低尿微量白蛋白的泡腾片及其制备方法和应用，能够明显降低24小时尿微量白蛋白/肌酐水平，保护肾脏和改善肾功能，降低痛风性关节炎的复发率，并且对人体无毒副作用。
Description
技术领域
本申请涉及一种降低尿微量白蛋白的泡腾片及其制备方法和应用，属于药品、食品和保健品技术领域。
背景技术
痛风是一种常见且复杂的关节炎类型，关节部位出现严重的疼痛、水肿、红肿和炎症，是典型的体内代谢出现问题。痛风发作的诱因主要由于摄入过多的嘌呤，使血尿酸水平升高。
当下降低尿酸生成和碱化尿液是高尿酸和痛风病人治疗的措施包括饮食控制和药品控制，单纯靠控制饮食来降低血尿酸作用是有限的，一部分患者还得需要得到治疗，进行药物的干预治疗，降低尿酸的药物经临床试验，都具有较大的副作用：多排尿酸的同时也把人体其它微量元素也排出体外，会造成低血钠、低血钾、低血钙，不能长期服用，而且还对肝、肾有副作用，所以治疗尿酸高、控制痛风我们应当找到更健康科学的方法。
目前，市场上适用于人们预防与辅助性治疗尿酸高、控制痛风的功能性食品未见报道；因此，有必要研制一种预防与辅助性治疗尿酸高、控制痛风的功能性食品，以满足人们的迫切需求。
发明内容
为了解决上述问题，提供了一种降低尿微量白蛋白的泡腾片及其制备方法和应用，能够明显降低24小时尿微量白蛋白/肌酐水平，保护肾脏和改善肾功能，降低痛风性关节炎的复发率，并且对人体无毒副作用。
本发明采用如下技术方案：
一种降低尿微量白蛋白的泡腾片，包括如下原料制备而成：酸樱桃果粉、异麦芽酮糖、甜菊糖苷、柠檬酸、碳酸钠、柠檬酸钠、柠檬酸钾、山梨糖醇。
可选地，包括如下重量配比的原料制备而成：
酸樱桃果粉12-20份、异麦芽酮糖4.0-5.0份、甜菊糖苷0.4-0.8份、柠檬酸40-47份、碳酸钠18-24份、柠檬酸钠4.5-5.5份、柠檬酸钾4.5-5.5份、山梨糖醇4.8-5.5份。
可选地，包括如下重量配比的原料制备而成：
酸樱桃果粉13份、异麦芽酮糖5.0份、甜菊糖苷0.45份、柠檬酸45份、碳酸钠21.75份、柠檬酸钠4.9份、柠檬酸钾4.9份、山梨糖醇5份。
酸樱桃具有降低尿酸，缓解痛风，改善睡眠的作用，对肝肾和其它器官没有任何刺激；异麦芽酮糖具有抑制脂肪积累，不引起肥胖，不引起血糖上升和胰岛素上升的作用；甜菊糖苷具有降血糖、降血脂、抗炎抗氧化的作用。
可选地，所述酸樱桃果粉是由如下方法制备得到：将酸樱桃果实果汁或水提物浓缩，喷雾干燥，即得酸樱桃果粉。
可选地，所述酸樱桃的品种选自Montmorency、Balaton、奥德、Erdi fubileum、Debreceni botermo、Oblacinska和Lutovka中的一种或多种。
可选地，所述酸樱桃果粉的纯度为50-75％。
根据本申请的另一个方面，提供了根据上述任一项所述的泡腾片的制备方法，包括：
将柠檬酸、柠檬酸钠和柠檬酸钾打粉备用，然后按重量配比称取各原料，混匀，压片，即得泡腾片。
根据本申请的又一个方面，提供了根据上述任一项所述的泡腾片在降低尿微量白蛋白的药品、食品或保健品中的应用。
可选地，所述泡腾片能够降低24小时尿微量白蛋白/肌酐。
可选地，所述泡腾片还能够保护肾脏和改善肾功能。
本申请的有益效果包括但不限于：
1.本申请的降低尿微量白蛋白的泡腾片，酸樱桃果粉抗氧化、抗炎和降尿酸的天然活性成分与功效，保留了酸樱桃天然的红色、香气和口感，更适于青少年高尿酸血症与痛风患者；柠檬酸钠和柠檬酸钾具有碱化尿液的功效，其中柠檬酸根是钙盐结石抑制因子，不但阻止尿酸盐和钙盐结石的形成，而且促进尿酸盐结晶或结石及钙盐结石的溶解；异麦芽酮糖具有抑制脂肪积累，不引起肥胖，不引起血糖上升和胰岛素上升的作用；甜菊糖苷具有降血糖、降血脂、抗炎抗氧化的作用；将药食同源的各原料制备成泡腾片既便于产品的贮存、运输和包装，且口感良好，便于患者使用。
2.本申请的降低尿微量白蛋白的泡腾片，崩解速度快、发泡量大、不易吸潮、质量稳定，并且对胃肠道刺激轻，碱化尿液的同时还具有溶石作用，能够明显降低24小时尿微量白蛋白/肌酐水平，保护肾脏和改善肾功能，降低痛风性关节炎的复发率，并且对人体无毒副作用。
3.本申请的降低尿微量白蛋白的泡腾片为食品级别，更加安全，充分利用各原料特性，降低尿微量白蛋白含量，保护肾脏和改善肾功能，缓解患者的痛风症状。
4.本申请的降低尿微量白蛋白的泡腾片，制备工艺合理，条件温和，便于操作，能够确保各原料的功能特效充分发挥。
附图说明
此处所说明的附图用来提供对本申请的进一步理解，构成本申请的一部分，本申请的示意性实施例及其说明用于解释本申请，并不构成对本申请的不当限定。在附图中：
图1为本申请实施例涉及的三组随访期间eGFR变化图。
图2为本申请实施例涉及的三组随访期间24小时尿微量白蛋白/肌酐变化图。
图3为本申请实施例涉及的三组随访期间24小时UACR变化幅度图。
图4为本申请实施例涉及的三组随访期间痛风石体积(双源CT)变化1 图。
图5为本申请实施例涉及的三组随访期间痛风石体积(双源CT)变化2 图。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚，下面将对本发明实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者，按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者，均为可以通过市售购买获得的常规产品。
实施例1
一种降低尿微量白蛋白的泡腾片，包括如下重量配比的原料制备而成：
酸樱桃果粉12份、异麦芽酮糖4.0份、甜菊糖苷0.4份、柠檬酸40份、碳酸钠18份、柠檬酸钠4.5份、柠檬酸钾4.5份、山梨糖醇4.8份。
制备方法包括以下步骤：
选取Erdi fubileum酸樱桃；然后将酸樱桃水提物浓缩，喷雾干燥，即得纯度为50％的酸樱桃果粉；随后将柠檬酸、柠檬酸钠和柠檬酸钾打粉备用，按重量配比称取各原料，混匀，压片，即得厚度为0.5cm、直径为2.55cm的泡腾片。
实施例2
一种降低尿微量白蛋白的泡腾片，包括如下重量配比的原料制备而成：
酸樱桃果粉20份、异麦芽酮糖4.5份、甜菊糖苷0.8份、柠檬酸47份、碳酸钠24份、柠檬酸钠5.5份、柠檬酸钾5.5份、山梨糖醇5.5份。
制备方法包括以下步骤：
选取质量比为1：1：1的Debreceni botermo、Oblacinska、Lutovka酸樱桃；然后将酸樱桃果实果汁浓缩，喷雾干燥，即得纯度为63％的酸樱桃果粉；随后将柠檬酸、柠檬酸钠和柠檬酸钾打粉备用，按重量配比称取各原料，混匀，压片，即得厚度为0.5cm、直径为2.55cm的泡腾片。
实施例3
一种降低尿微量白蛋白的泡腾片，包括如下重量配比的原料制备而成：
酸樱桃果粉13份、异麦芽酮糖5.0份、甜菊糖苷0.45份、柠檬酸45份、碳酸钠21.75份、柠檬酸钠4.9份、柠檬酸钾4.9份、山梨糖醇5份。
制备方法包括以下步骤：
选取质量比为1：1：1的Montmorency、Balaton、奥德酸樱桃；然后将酸樱桃果实果汁浓缩，喷雾干燥，即得纯度为75％的酸樱桃果粉；随后将柠檬酸、柠檬酸钠和柠檬酸钾打粉备用，按重量配比称取各原料，混匀，压片，即得厚度为0.5cm、直径为2.55cm的泡腾片。
实施例4
与实施例3的区别在于：原料中不包括13份酸樱桃果粉，并将5.0份异麦芽酮糖和0.45份甜菊糖苷替换为18.45份乳糖。
试验例1
1.降低尿微量白蛋白的泡腾片崩解时限检测
烧杯中加入200ml 25℃的蒸馏水，将泡腾片投入烧杯中并计时，待泡腾片完全崩解停止计时，崩解时间见表2。
2.降低尿微量白蛋白的泡腾片的感官评价
随机挑选男女各5名(其中感官评价专家型人员1名，有经验型3名，无经验型3名，消费者型3名)，取一片本发明的产品崩解于300ml水中，评价人员于感官品评室试用产品后，对产品的色泽、香味、口感进行评价，感官评价标准见表1，测定结果见表2。
表1感官评价标准
表2试验结果
| 崩解时间 | 色泽 | 香味 | 口感 | 总体评价 | |
| 实施例1 | 2’18” | 5 | 4 | 4 | 4 |
| 实施例2 | 2’36” | 4 | 5 | 4 | 4 |
| 实施例3 | 1’50” | 5 | 5 | 5 | 5 |
| 实施例4 | 2’12” | 3 | 2 | 1 | 2 |
由表2可以看出，本发明的产品在色泽、香味、口感等方面的感官评价得分均较高，总体评价较好，10位感官评价人员都非常喜欢本发明的产品。
试验例2临床试验
1.受试者描述
本试验共入组282例受试者，最终254例(90.07％)完成所有访视，28 例受试者在研究结束前提前退出。碳酸氢钠组、风零组和风零+组分别有86例、 86例和82例完成全部访视。
退组原因：21人因自身依从性原因退组，5人因其它疾病退组，2人因痛风发作退组。
2.给药方案
碳酸氢钠组：非布司他20mg qd+小苏打1g tid(初始治疗)；非布司他 40mg qd+小苏打1g tid(基于尿酸水平调整)；
风零组：非布司他20mg qd+实施例4泡腾片3.5g bid，非布司他40mg qd+ 实施例4泡腾片3.5g bid(基于尿酸水平调整)；
风零+组：非布司他20mg qd+实施例3泡腾片3.5g bid，非布司他40mg qd+ 实施例3泡腾片3.5g bid(基于尿酸水平调整)；
每组94受试者，每日服用2次，服用90日。
3.人口统计学及其他基线特征
完成本研究的254例受试者，均为男性且符合2015ACR/EULAR痛风诊断标准。基线特征见表3：
表3
4.疗效分析
4.1尿pH变化情况
随访期间尿pH6-7、6.2-6.9及pH<5.5所占比例：访视第4周，风零组尿 pH介于6-7所占比例明显高于碳酸氢钠组和风零+组(P＝0.015)，余差异无显著性，具体见表4：
表4
4.2治疗期间血尿酸达标情况
达标率：对随访期间3组UA<420μmol/L、UA<360μmol/L、UA<300μmol/L 的人数进行统计发现：各组各时间点血尿酸达标率均无统计学差异，具体见表 5：
表5
4.3肾功能变化
(1)eGFR(校正肾小球滤过率)：与基线相比，第12周，碳酸氢钠组 eGFR有降低趋势，但差异无显著性(P＝0.402)，风零组eGFR明显降低 (P＝0.022)，风零+组eGFR有升高趋势，但差异无显著性(P＝0.396)。与基线相比，第8周，风零+组eGFR明显升高(P<0.001)，余各组均无明显变化，见图1。
(2)24小时UACR(尿微量白蛋白/尿肌酐)：与基线相比，第12周， 24小时UACR，碳酸氢钠组有降低趋势，但差异无显著性(P＝0.263)，风零组明显升高(P＝0.006)，风零+组明显降低(P＜0.001)，见图2。
(3)随访12周24小时UACR较基线变化幅度：风零+组与碳酸氢钠组相比，UACR下降幅度更高，有显著性差异(P＝0.002)。风零+组与风零组相比，UACR下降幅度更高，有显著性差异(P＝0.012)；风零组与碳酸氢钠组间差异无统计学意义，见图3。
4.4尿酸盐结晶体积较首次访视时的变化
(1)双源CT结果显示：碳酸氢钠组末次访视痛风石体积较基线明显减小 (P＝0.001)，风零组末次访视痛风石体积较基线明显减小(P＝0.002)，风零+ 组末次访视痛风石体积较基线明显减小(P<0.001)，见图4。
(2)双源CT结果显示：各组间末次访视痛风石体积较基线的减少幅度无明显差异(P＝0.668)。关节B超结果显示，末次访视痛风石体积较基线的减少幅度无显著差异(P＝0.824)，见图5。
4.5痛风急性发作情况
(1)痛风急性发作至少1次：碳酸氢钠组40人，占46.5％，风零组33 人，占38.4％，风零+组33人，占40.2％，碳酸氢钠组高于风零和风零+组，但差异无显著性。
(2)痛风急性发作患者≥2次：碳酸氢钠组，21人，占24.4％，风零组12人，占14.0％，风零+组11人，占13.4％，碳酸氢钠组高于风零和风零+组，但差异无显著性，结果见表6。
表6
| 碳酸氢钠组 | 风零组 | 风零+组 | P | |
| 符合方案集 | ||||
| 4week | 24(27.9％) | 14(16.7％) | 16(19.8％) | 0.183 |
| 8week | 27(32.5％) | 20(23.5％) | 14(17.5％) | 0.080 |
| 12week | 19(22.1％) | 15(17.4％) | 14(17.1％) | 0.647 |
| ≥1次 | 40(46.5％) | 33(38.4％) | 33(40.2％) | 0.527 |
| ≥2次 | 21(24.4％) | 12(14.0％) | 11(13.4％) | 0.101 |
| 全分析集 | ||||
| 4week | 25(27.5％) | 16(17.4％) | 18(20.2％) | 0.234 |
| 8week | 28(32.2％) | 22(24.4％) | 14(16.7％) | 0.062 |
| 12week | 19(21.8％) | 15(17.2％) | 14(17.1％) | 0.662 |
| ≥1次 | 42(44.7％) | 36(37.9％) | 35(37.6％) | 0.535 |
| ≥2次 | 21(22.3％) | 13(13.7％) | 11(11.8％) | 0.111 |
以上所述，仅为本申请的实施例而已，本申请的保护范围并不受这些具体实施例的限制，而是由本申请的权利要求书来确定。对于本领域技术人员来说，本申请可以有各种更改和变化。凡在本申请的技术思想和原理之内所作的任何修改、等同替换、改进等，均应包含在本申请的保护范围之内。
Claims (10)
1.一种降低尿微量白蛋白的泡腾片，其特征在于，包括如下原料制备而成：酸樱桃果粉、异麦芽酮糖、甜菊糖苷、柠檬酸、碳酸钠、柠檬酸钠、柠檬酸钾、山梨糖醇。
2.根据权利要求1所述的降低尿微量白蛋白的泡腾片，其特征在于，包括如下重量配比的原料制备而成：
酸樱桃果粉12-20份、异麦芽酮糖4.0-5.0份、甜菊糖苷0.4-0.8份、柠檬酸40-47份、碳酸钠18-24份、柠檬酸钠4.5-5.5份、柠檬酸钾4.5-5.5份、山梨糖醇4.8-5.5份。
3.根据权利要求2所述的降低尿微量白蛋白的泡腾片，其特征在于，包括如下重量配比的原料制备而成：
酸樱桃果粉13份、异麦芽酮糖5.0份、甜菊糖苷0.45份、柠檬酸45份、碳酸钠21.75份、柠檬酸钠4.9份、柠檬酸钾4.9份、山梨糖醇5份。
4.根据权利要求3所述的降低尿微量白蛋白的泡腾片，其特征在于，所述酸樱桃果粉是由如下方法制备得到：将酸樱桃果实果汁或水提物浓缩，喷雾干燥，即得酸樱桃果粉。
5.根据权利要求4所述的降低尿微量白蛋白的泡腾片，其特征在于，所述酸樱桃的品种选自Montmorency、Balaton、奥德、Erdi fubileum、Debreceni botermo、Oblacinska和Lutovka中的一种或多种。
6.根据权利要求4所述的降低尿微量白蛋白的泡腾片，其特征在于，所述酸樱桃果粉的纯度为50-75％。
7.根据权利要求1-6任一项所述的泡腾片的制备方法，其特征在于，包括：
将柠檬酸、柠檬酸钠和柠檬酸钾打粉备用，然后按重量配比称取各原料，混匀，压片，即得泡腾片。
8.根据权利要求1-6任一项所述的泡腾片在降低尿微量白蛋白的药品、食品或保健品中的应用。
9.根据权利要求8所述的应用，其特征在于，所述泡腾片能够降低24小时尿微量白蛋白/肌酐。
10.根据权利要求9所述的应用，其特征在于，所述泡腾片还能够保护肾脏和改善肾功能。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210821693.5A CN115105482A (zh) | 2022-07-13 | 2022-07-13 | 一种降低尿微量白蛋白的泡腾片及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210821693.5A CN115105482A (zh) | 2022-07-13 | 2022-07-13 | 一种降低尿微量白蛋白的泡腾片及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115105482A true CN115105482A (zh) | 2022-09-27 |
Family
ID=83333381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210821693.5A Pending CN115105482A (zh) | 2022-07-13 | 2022-07-13 | 一种降低尿微量白蛋白的泡腾片及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115105482A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922178A (zh) * | 2015-06-09 | 2015-09-23 | 德令哈林生生物科技开发有限公司 | 一种降血糖泡腾片剂及其用途 |
| CN105495258A (zh) * | 2015-12-07 | 2016-04-20 | 广东盛元中天生物科技有限公司 | 一种有助降尿酸的水果饮料 |
| CN108295101A (zh) * | 2018-03-23 | 2018-07-20 | 光谷迈德（武汉）慢性病研究院有限公司 | 一种可用于治疗痛风及高尿酸疾病的碱性泡腾片 |
| CN111685246A (zh) * | 2020-06-30 | 2020-09-22 | 山东国和堂制药有限公司 | 一种含玫瑰花精华及玫瑰提香的饮料及其制备方法 |
-
2022
- 2022-07-13 CN CN202210821693.5A patent/CN115105482A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922178A (zh) * | 2015-06-09 | 2015-09-23 | 德令哈林生生物科技开发有限公司 | 一种降血糖泡腾片剂及其用途 |
| CN105495258A (zh) * | 2015-12-07 | 2016-04-20 | 广东盛元中天生物科技有限公司 | 一种有助降尿酸的水果饮料 |
| CN108295101A (zh) * | 2018-03-23 | 2018-07-20 | 光谷迈德（武汉）慢性病研究院有限公司 | 一种可用于治疗痛风及高尿酸疾病的碱性泡腾片 |
| CN111685246A (zh) * | 2020-06-30 | 2020-09-22 | 山东国和堂制药有限公司 | 一种含玫瑰花精华及玫瑰提香的饮料及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2124972B1 (de) | Verwendung einer zusammensetzung aus mineralstoffen und gegebenenfalls acetogenen und/oder butyrogenen bakterien zur vermeidung oder reduzierung von gasbildung im dickdarm eines säugetiers und dadurch bedingter abdominaler beschwerden | |
| CN107343657B (zh) | 生酮饮食配方粉 | |
| US20180200284A1 (en) | Multi-functional Composition and Preparation Method and Application Thereof | |
| CN103432161B (zh) | 多种维生素矿物质泡腾片及其制备方法 | |
| CN101889679B (zh) | 一种具有解酒保肝作用的组合物及其在食品、保健食品中的应用 | |
| US20200297789A1 (en) | Composition for reducing cancer cachexia or weight loss caused by anticancer drug therapy or radiation therapy comprising ginseng extract having increased ginsenoside rg3 and rh2 | |
| CN104758920A (zh) | 一种基于药食同源的痛风保健品 | |
| JP6345243B2 (ja) | 円武扇発酵物含有食品または飲料組成物 | |
| CN102160664A (zh) | 儿童营养饮料 | |
| KR20210060717A (ko) | 피로회복을 위한 경구용 수액분말 조성물 및 이의 제조방법 | |
| JPH0614746A (ja) | 健康飲料 | |
| EP3290041B1 (en) | Oral care composition | |
| CN107624068B (zh) | 包含肉桂醛和锌的组合物及此类组合物的使用方法 | |
| KR101721145B1 (ko) | Ｌ-카르니틴 구연산 마그네슘을 포함하는 배변촉진 겸용 다이어트용 식품 조성물 | |
| US20060263385A1 (en) | Composition to relieve side effects of alcohol intoxication | |
| CN115105482A (zh) | 一种降低尿微量白蛋白的泡腾片及其制备方法和应用 | |
| KR20190140737A (ko) | 디톡스-다이어트 물질을 포함하는 식초 조성물의 제조방법 | |
| CN107897621A (zh) | 一种鲍鱼泡腾片生产方法 | |
| CN107348490A (zh) | 一种复方钙 | |
| WO2008096171A2 (en) | Natural laxative composition comprising prunes, raisins, apricots, dates, figs, olive oil, senna and honey | |
| CN101370555A (zh) | (-)-表没食子儿茶素没食子酸酯的新型用途 | |
| CN101347463A (zh) | 一种用于预防复发和治疗胃溃疡的药物组合物 | |
| KR20040097813A (ko) | 식욕억제, 체지방 감소 및 배변 활성화등 3가지 기능을 갖는 항비만 기능성 조성물 | |
| JP6533784B2 (ja) | 眼の疲れ改善剤 | |
| CN103948591B (zh) | 一种减肥药剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |